Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.
Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.|Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
Andrew
A
Rowland
Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.|School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
Mafalda M
MM
Dias
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
Michael D
MD
Wiese
Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
Ganessan
G
Kichenadasse
Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
Ross A
RA
McKinnon
Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
Christos S
CS
Karapetis
Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.|Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.
Michael J
MJ
Sorich
D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*
D066246:ErbB Receptors; D048493:Proto-Oncogene Proteins B-raf